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A bioengineered skeletal muscle tissue as an alternative for autologous tissue flaps, which mimics 
the structural and functional characteristics of the native tissue, is needed for reconstructive surgery. 
Rapid progress in the cell-based tissue engineering principle has enabled in vitro creation of cellularized 
muscle-like constructs; however, the current fabrication methods are still limited to build a three-
dimensional (3D) muscle construct with a highly viable, organized cellular structure with the potential 
for a future human trial. Here, we applied 3D bioprinting strategy to fabricate an implantable, 
bioengineered skeletal muscle tissue composed of human primary muscle progenitor cells (hMPCs). 
The bioprinted skeletal muscle tissue showed a highly organized multi-layered muscle bundle made 
by viable, densely packed, and aligned myofiber-like structures. Our in vivo study presented that the 
bioprinted muscle constructs reached 82% of functional recovery in a rodent model of tibialis anterior 
(TA) muscle defect at 8 weeks of post-implantation. In addition, histological and immunohistological 
examinations indicated that the bioprinted muscle constructs were well integrated with host vascular 
and neural networks. We demonstrated the potential of the use of the 3D bioprinted skeletal muscle 
with a spatially organized structure that can reconstruct the extensive muscle defects.
Skeletal muscle injuries due to trauma or tumor ablation usually require a reconstructive procedure to restore 
normal tissue function. In the United States alone, approximately 4.5 million patients undergo reconstructive 
surgeries annually1. In many cases, extensive muscle defect results in functional impairment with severe physi-
cal deformity2,3. The standard of care is an autologous muscle pedicle flap from adjacent regions; however, host 
muscle tissue availability and donor site morbidity may make this strategy challenging4. Recent advances in cell 
therapy provide alternatives to regenerate muscle tissue for functional augmentation5. Injection of cultured cells 
has shown some efficacy6–8; however, this approach can be unrealistic to treat the muscle defect due to low cell 
engraftment and survival of the injected cells9,10. Therefore, bioengineering of an implantable muscle construct 
that can restore the normal muscle function is an attractive possibility9,11,12.
In recent decades, researchers have focused on mimicking the ultrastructure of native muscle tissue that is 
composed of highly oriented myofibers. The structural organization of skeletal muscle with multiple myofiber 
bundles is vital for the muscle contraction and functionality13,14. Controlling organization of bioengineered mus-
cle tissue in vitro should be essential for functional tissue restoration after implantation in vivo15. Thus, the ability 
to recapitulate the organization and function of the native skeletal muscle is the most important element in bio-
engineered skeletal muscle tissues16. To build the muscular organization using the alignment of single cells in the 
bioengineered skeletal muscle constructs in vitro, several attempts have been reported. Due to recent advance-
ment in microfabrication technologies, the cellular orientation of muscle cells has been controlled via microtopo-
graphic cues17–24. The mechanical stimulation25,26 and electrical fields21,27 have also been tested to align the muscle 
cells in biomaterial scaffolds. These strategies could pre-align the muscle cells and improve their functionality in 
vitro; however, they only allowed micron-scale tissue or single-layered muscle bundle constructions that may be 
not suitable for treating extensive muscle defect10,28–32.
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Recent advances in 3D bioprinting technologies enable to bioengineer various functional tissue constructs 
with complex geometry by building up cell-laden hydrogels in a layer-by-layer fashion33–35. We have previously 
developed a novel bioprinting method, integrated tissue-organ printing (ITOP) system that can generate a 3D 
freeform shape with multiple cell types and biomaterials, resulting in the fabrication of various human-scale tis-
sue architectures for translational applications36. In our previous work, we utilized this ITOP system to create an 
organized muscle construct 15 × 5 × 1 mm3 in dimension containing mouse myoblast cell line, which composed 
of pre-aligned muscle fibers within multi-layered myofiber bundles. The outcomes showed that the bioprinted 
organized muscle constructs could mature into functional muscle in vivo when implanted subcutaneously in rats.
Based on this initial success, we investigated the feasibility of using 3D bioprinted muscle constructs for treat-
ing extensive skeletal muscle defects. In this study, we created skeletal muscle constructs (mm3–cm3 scale) with 
the structural integrity and skeletal muscle tissue organization for functional muscle tissue reconstruction. Also, 
muscle progenitor cells (MPCs) used in this study were isolated from human muscle tissue biopsies for further 
clinical relevance. Evaluations for the muscle characteristics in vitro were performed. Muscle tissue regeneration 
and functional recovery were evaluated using a rodent muscle defect model of 30–40% of tibialis anterior (TA) 
muscle loss with ablation of extensor digitorum longus (EDL) and extensor hallucis longus (EHL) muscles10 to 
determine the feasibility to treat critical-sized skeletal muscle injuries.
Results
3D bioprinted muscle constructs with structural mimicry in vitro. A bioengineered skeletal muscle 
construct with the ultrastructural organization similar to the native muscle was designed and fabricated by the ITOP 
technology (Fig. 1A,B). This muscle construct consisted of three components: (i) a human muscle progenitor cell 
(hMPC)-laden hydrogel bioink, (ii) a sacrificing acellular gelatin hydrogel bioink, and (iii) a supporting poly(ε-caprol-
actone) (PCL) polymer (Fig. 1C). To create the cellular organization in the printed skeletal muscle structure, multi-
ple strips of the cell-laden bioinks were patterned in parallel to one another, which were anchored to the PCL pillar 
structure (Fig. 1D). The thickness of the printed constructs was determined and controlled by the number of stacking 
layers of cell-laden bioinks. A printed PCL pillar structure allowed to align printed cells longitudinally in response to 
mechanical cues and to maintain the structural integrity of multi-layered muscle constructs after printing. To maintain 
the viability of printed cells within large-scale muscle constructs (up to 15 × 15 × 15 mm3, Fig. 1E), we created micro-
channels between the cell-laden patterns based on the diffusion limit of oxygen and nutrients, ~200 µm10,32 (Fig. 1F).
We evaluated the bioprinted skeletal muscle constructs containing 3 × 106 cells/ml of hMPCs in vitro on the 
viability, differentiation capacity to form multinucleated myofibers, and the cellular orientation in the printed 
constructs. The printed constructs were cultured for 1 day in growth medium and then induced differentiation for 
9 days in differentiation medium. In the live/dead analysis, the bioprinted muscle constructs had highly organ-
ized multiple myofiber bundles in which hMPCs were longitudinally aligned along the printed pattern direction 
(Supplementary Fig. 1A). Microchannels between the bundles of myofibers were also observed. The maturation of 
the bioprinted muscle was confirmed by myosin heavy chain (MHC) immunostaining (Supplementary Fig. 1B).
Figure 1. Bioprinting of skeletal muscle. (A) Design concept using 3D CAD modeling and (B) motion 
program generation of the bioprinted muscle construct. The code includes XYX stage movement and actuating 
pneumatic pressure. (C,D) Bioprinting process using ITOP system. (C) The motion program was transferred 
to the operating computer of ITOP. The cell-laden bioink containing hMPCs, the acellular sacrificing hydrogel, 
and the supporting PCL pillar were loaded in the multi-dispensing modules. (D) All three components were 
printed in a layer-by-layer fashion. (E) The bioprinted skeletal muscle constructs composed of multi-layered 
myofiber bundles were fabricated up to 15 × 15 × 15 mm3 in dimension. The thickness of the printed muscle 
construct was determined by controlling the number of stacking myofiber bundles. (F) Microchannels in the 
constructs created after the removal of the sacrificial patterns to maintain the viability of printed cells.
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To determine the importance of organized architecture and microchannel structure on skeletal muscle con-
struction, the bioprinted and non-printed (hMPCs in hydrogel without printing) constructs were prepared with 
the same cell density (30 × 106 cells/ml) and dimension (10 × 10 × 3 mm3), and the cell viability and differenti-
ation were measured during in vitro culture. In the live/dead assay staining, the bioprinted muscle constructs 
showed high cell viability (86.4 ± 3.5%) compared to the non-printed muscle constructs (63.0 ± 6.7%) at 1 day in 
culture; however, most of the cells in the non-printed constructs died at 5 days, while high cell viability was main-
tained in the printing constructs (Fig. 2A,B; n = 4 and 4 random fields/sample, Student t-test, *P < 0.05). MHC+ 
myofibers in the bioprinted constructs showed an 11.53-fold increase when compared with the non-printed 
constructs at 7 days of differentiation, and the myofibers were densely packed and aligned (Fig. 2C,D; n = 3 
and 4–7 random fields/sample, Student t-test, *P < 0.05). In the bioprinted constructs, cross-striated myofib-
ers surrounded by basal lamina-like matrices were observed in double-immunostaining for α-sarcomeric actin 
(α-SA) and laminin, indicating the muscle contractile properties (Fig. 2E–G, n = 3 and 4–7 random fields/sam-
ple, Student t-test, *P < 0.05). These results show that the 3D printed organized muscle structure can accelerate 
the tissue maturation, while the microchannel structure can allow the diffusion of nutrient and oxygen to main-
tain the cell viability in the printed constructs.
Effect of initial cell density in bioprinted muscle construct. We printed the organized muscle con-
structs with various cell densities (10, 20, 30, and 50 × 106 cells/ml) and evaluated the cell viability and differ-
entiation in vitro. Approximately 90% live cells were determined at 1 day in all constructs with no significant 
differences (Fig. 3A,B; n = 6 and 5 random fields/sample, ANOVA and post hoc Tukey test), and approx. 25% 
apoptotic cells were detected at 6 days in culture with no significant differences among groups (Fig. 3C; n = 3 and 
5 random fields/sample, ANOVA and post hoc Tukey test) as confirmed by TUNEL staining assay. The differen-
tiated myofibers were strongly expressed MHC in all groups with cells aligned longitudinally in the bioprinted 
constructs at 6 days in culture (Fig. 3D). The density of MHC+ myofibers tended to increase with increasing cell 
density in the bioprinted muscle constructs. These results indicate that the ITOP system could build the skeletal 
muscle constructs with highly viable and differentiated into highly aligned, densely packed myofibers over a 
broad range of cell densities.
Figure 2. In vitro evaluations of bioprinted muscle constructs compared with non-printed constructs. 
(A) Representative Live/Dead staining images and (B) cell viability (%) at 1 and 5 days in culture (n = 4, 4 
random fields/sample, *P < 0.05, **not measurable because of too confluence - % viability was over 90%). 
(C) Immunofluorescent staining for MHC after 7 day-differentiation and (D) quantification of area of 
MHC + myofibers (n = 3, 4–7 random images/sample, *P < 0.05). Human MPCs in the construct showed 
enhanced myofiber formation with unidirectional cell alignment. (E) Double-immunostaining for α-SA (red)/
laminin (green) indicates the presence of cross-striated myofibers surrounded by laminin matrix in the printed 
construct. Quantification of (F) α-SA+ area (%) and (G) laminin+ area (%) (n = 3, *P < 0.05).
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To determine the optimal cell density in the bioprinted muscle constructs in terms of the dimensional main-
tenance in vivo, the bioprinted muscle constructs (10 × 10 × 3 mm3) with different cell densities (10, 20, 30, and 
50 × 106 cells/ml of hMPCs) were implanted subcutaneously in athymic mice (total 48 nu/nu mice, male, 6–8 
weeks old). Hematoxylin and eosin (H&E) stained images showed that the bioprinted muscle constructs of 
multi-layered, longitudinally aligned patterns were maintained until 4 weeks after implantation (Fig. 4A). The 
thickness of the implanted constructs (n = 4 and 3 random fields/sample) increased with cell density, but there 
was no significant difference between 30 × 106 cells/ml and 50 × 106 cells/ml groups at 1, 2, and 4 weeks (Fig. 4B; 
ANOVA and Tukey test, *P < 0.05 compared with 10 × 106 cells/ml, **P < 0.05 compared with 10 × 106 cells/ml 
and 20 × 106 cells/ml). In the 30 × 106 cells/ml and 50 × 106 cells/ml groups, the thickness of the construct was 
maintained until 2 weeks and decreased at 4 weeks.
The retrieved muscle constructs were also characterized using double-immunostaining of MHC and human 
leukocyte antigen A (HLA) antibodies. MHC+ myofibers were identified in all implanted bioprinted muscle con-
structs at 2 weeks, and they were aligned longitudinally along the implants (Fig. 5A). Newly formed myofibers 
in the implanted constructs were measured as the number of MHC+ myofibers (/mm2) and the area of MHC+ 
myofibers (mm2/mm2) (Fig. 5B,C; n = 4 and 3 random fields/sample). These parameters were increased with 
increasing the cell density in the implanted constructs, but there was not significantly different between 30 × 106 
cells/ml and 50 × 106 cells/ml groups at 1 and 2 weeks after implantation (ANOVA and Tukey test, *P < 0.05 
compared with 10 × 106 cells/ml at 1 week, **P < 0.05 compared with 10 and 20 × 106 cells/ml at 1 week, 
†P < 0.05 compared with 10 × 106 cells/ml at 2 weeks, and ††P < 0.05 compared with 10 and 20 × 106 cells/ml at 
2 weeks). MHC+/HLA+ double-immunostained images determined that newly formed myofibers were derived 
from the implanted bioprinted muscle constructs (Fig. 5A). There was no significant difference in a number 
of HLA+ myofibers (/mm2) and area of HLA+ myofibers (/mm2) between 30 and 50 × 106 cells/ml at 2 weeks 
(Fig. 5D,E; Student t-test). In addition, over 80% MHC+ myofibers in all groups were expressed by HLA+ at 2 
Figure 3. In vitro cell density optimization. (A) Live/dead staining images and (B) quantification of bioprinted 
muscle constructs with cell densities of 10, 20, 30, and 50 × 106 cells/ml at 1 day in culture (n = 6, 5 random 
fields/sample, no significant difference). (C) TUNEL assay of bioprinted muscle constructs after 6 days 
in culture. Apoptotic cells were calculated with different cell densities (n = 3, 5 random fields/sample, no 
significant difference). (D) MHC immunofluorescent images of bioprinted muscle constructs at 6 days in 
culture (after 5-day differentiation). Representative immunofluorescent images for MHC (red) showed that 
bioprinted hMPCs in the constructs with different cell densities were formed into longitudinally aligned 
myofibers.
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weeks of implantation. Vascularization and neural integration were also demonstrated with von Willebrand factor 
(vWF) and neurofilament (NF)/alpha-Bungarotoxin (α-Btx) double-immunostaining at 2 weeks, respectively 
(Supplementary Fig. 2). The vWF+ vessels and NF+ nerves were observed throughout the implants and in the 
Figure 4. In vivo cell density optimization on dimensional maintenance. (A) H&E-stained images of 
longitudinal cross-sections of bioprinted muscle constructs with different cell densities at 1, 2 and 4 weeks after 
implantation. (B) The thickness of bioprinted muscle constructs as measured by H&E-stained sections (n = 4, 
3 random regions/sample). Thickness of the constructs increased with cell density, but there was no significant 
difference between 30 and 50 × 106 cells/ml at 2 weeks and 4 weeks (*P < 0.05 compared with 10 × 106 cells/ml, 
**P < 0.05 with 10 × 106 cells/ml and 20 × 106 cells/ml).
Figure 5. Ectopic skeletal muscle regeneration. (A) Representative immunofluorescent images for MHC (red)/HLA 
(green) at 2 weeks after implantation. Double-immunostained MHC+/HLA+ myofibers in bioprinted constructs 
indicate newly formed skeletal muscle. (B) Numbers of MHC+ myofibers and (C) areas of MHC+ myofibers (n = 4, 3 
random regions/sample). There is an increasing trend of skeletal muscle tissue formation with increasing cell density, 
but no significant difference between 30 and 50 × 106 cells/ml at 1 week and 2 weeks after implantation (*P < 0.05 
compared with 10 × 106 cells/ml at 1 week, **P < 0.05 compared with 10 and 20 × 106 cells/ml at 1 week, †P < 0.05 
compared with 10 × 106 cells/ml at 2 weeks, and ††P < 0.05 compared with 10 and 20 × 106 cells/ml at 2 weeks). 
(D) Numbers of HLA + myofibers and (E) areas of HLA+ myofibers (n = 4, 3 random regions/sample). There is no 
significant difference between 30 × 106 cells/ml and 50 × 106 cells/ml at 2 weeks after implantation.
www.nature.com/scientificreports/
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surrounding tissues (white arrows). Results indicate that the optimal cell density of the bioprinted muscle con-
structs is 30 × 106 cells/ml.
Structural and functional restoration by implantation of bioprinted muscle constructs. Based 
on the in vitro and in vivo results, we next investigated the feasibility of the bioprinted muscle constructs to restore 
the muscle function using the rat TA muscle defect model. A muscle defect was created by excision of 30–40% 
of original TA muscle mass following ablation of EDL and EHL muscles in nude rats (Supplementary Fig. 3A)10. 
This TA muscle defect causes irreversible anatomic and functional deficits for 6 months post-injury without any 
treatment37. The bioprinted muscle constructs were implanted into the defect region in TA muscle, and sham 
control (without defect), non-treated (defect only), gel only (non-printed and no cells), and non-printed (random 
structure with cells) constructs were used for comparison (30 RNU rats, n = 3, One-way ANOVA and Turkey test 
to compare group differences in each time point and Student t-test to compare time differences in each group). 
The in vivo functional analysis was performed by measuring tetanic muscle force of the muscle with peroneal 
nerve stimulation. We used the bioprinted muscle constructs with an initial cell density of 30 × 106 cells/ml. 
After in vitro culture, the bioprinted muscle constructs were implanted in the defect site following removal of 
the PCL frame to fit the defect region in TA muscle (10 × 7 × 3 mm3). In the gross examination of the harvested 
TA muscles, the surgically created defect resulted in severe muscular atrophy in the non-treated, gel only, and 
non-printed groups at 4 and 8 weeks post-injury, while the bioprinted group maintained their original muscle 
volume during the 8-week period (Supplementary Fig. 3B). More importantly, at 4 and 8 weeks after implanta-
tion, only the bioprinted muscle group showed a significant increase of the tetanic muscle force and TA muscle 
weight when compared with other groups (Fig. 6; ANOVA and Turkey test, **P < 0.05 at 4 weeks and †P < 0.05 
at 8 weeks). However, no significant differences in the tetanic muscle force and TA weight of the gel-only and 
non-printed groups were determined when compared with the non-treated group at 8 weeks after implantation. 
By 8 weeks, the muscle force in the bioprinted group reached to 85.0 ± 12.3 N*mm/kg that was 82% restoration 
of TA muscle force compared with normal TA muscle. TA muscle weight in bioprinted group increased 1.52 and 
1.54-fold compared to that in the non-printed group at 4 and 8 weeks, respectively. By 8 weeks, muscle weight had 
recovered up to 82.5 ± 2.4% of the contralateral normal TA muscle.
Newly formed myofibers and tissue maturation by implantation of bioprinted muscle con-
structs. Improved structural outcomes by implantation of the bioprinted muscle constructs were examined by 
histological and immunofluorescent analyses. The analyses were performed with longitudinal sections of the TA 
muscles to examine overall implanted regions and the alignment along with native muscle orientation. In H&E 
and Masson’s trichrome staining, the bioprinted muscle group showed superior muscle volume maintenance and 
myofiber formation with organized architecture, while the other groups showed limited muscle volume recovery 
and tissue development (Fig. 7 and Supplementary Fig. 4).
To identify the newly formed myofibers in the implanted region, we performed double-immunofluorescent 
staining of the retrieved TA muscles using MHC and HLA antibodies (Fig. 8A,B). Few MHC+ myofibers were 
determined in the gel-only and non-printed groups at 4 weeks after implantation. In the non-printed group con-
taining hMPCs, only a few HLA+ cells remained adjacent to the host muscle tissue at 4 and 8 weeks. In contrast, 
in the bioprinted group, a higher number of HLA+ human cells were detected throughout the implanted region 
at 4 and 8 weeks after implantation (Fig. 8C; n = 3, Student t-test, *P < 0.05 compared with the non-printed 
group, **P < 0.05 between 4 and 8 weeks). Notably, the bioprinted muscle constructs became more matured that 
significantly contributed to the muscle tissue regeneration, as confirmed by MHC+/HLA+ myofibers (Fig. 8D). 
The implanted hMPCs were continuously involved in the myofiber formation and maturation with increased 
Figure 6. Rat TA muscle defect model. (A) Tetanic force (N · mm/kg) and (B) TA muscle weight (% of 
contralateral normal TA muscle) were measured at 4 and 8 weeks after implantation (n = 3 per group, triple 
measures per sample). Tetanic force and muscle weight of bioprinted muscle constructs-implanted group had 
significantly increased when compared with other groups (*P < 0.05 compared with non-treated group at 
4 weeks, **P < 0.05 compared with non-treated, gel only, and non-printed groups at 4 weeks, and †P < 0.05 
compared with non-treated, gel only, and non-printed groups at 8 weeks).
www.nature.com/scientificreports/
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myofiber diameter at 8 weeks (Fig. 8E; cross-sectional analysis, n = 3, 3 random fields per sample, Student t-test, 
*P < 0.05). Furthermore, most MHC+/HLA+ myofibers in the TA muscle showed highly aligned and organized 
architecture. These results indicate that the implanted hMPCs in the bioprinted constructs are viable and matured 
with maintaining their cellular organization for reconstructing the extensive muscle defect injury.
Vascularization and neural integration of the implanted bioprinted muscle constructs were evaluated by 
double-immunofluorescent staining for vWF/α-smooth muscle actin (α-SMA) and triple-immunofluorescent 
staining for NF/acetylcholine receptor (AChR)/MHC and NF/AChR/HLA, respectively (Fig.  9 and 
Supplementary Fig. 5). Immunofluorescent images showed the implanted bioprinted muscle constructs were 
well-vascularized as confirmed by vWF+ and α-SMA+ vessels (Fig. 9A–C; n = 3, ANOVA and Turkey test, 
*P < 0.05 compared with non-treated and gel only groups at 4 weeks, **P < 0.05 compared with other groups at 4 
weeks, †P < 0.05 compared with non-treated and gel only groups at 8 weeks, and ††P < 0.05 compared with other 
groups at 8 weeks). Also, host nerve integration was determined by NF+ nerve fibers in the implanted region 
(Fig. 9D). Neuromuscular junction (NMJ) formation, as identified by NF+, AChR+, and MHC+, was clearly 
determined in the implanted region, and mature NMJs were observed at 8 weeks after implantation (Fig. 9D,E; 
n = 3 per group, 3 random fields per sample, ANOVA and Turkey test, **P < 0.05 compared with other groups at 
4 weeks and ††P < 0.05 compared with other groups at 8 weeks). Immunofluorescent staining for NF/AChR/HLA 
corresponding to NF/AChR/MHC indicated that the newly formed muscle in the bioprinted constructs could be 
integrated with host nerve system (Fig. 9D). These outcomes state that the 3D bioprinted muscle constructs can 
be functional by integration with the host vascular and nerve systems following implantation in the TA muscle 
defect.
Discussion
Bioengineering of an implantable muscle construct with structural and functional characteristics of native skel-
etal muscle is critical for reconstructive surgery. We previously developed the ITOP system that could gener-
ate 3D freeform shapes with multiple cell types and biomaterials, resulting in various tissue architectures with 
biomimetic features36,38–40. We also applied this system to fabricate the organized skeletal muscle construct of 
15 × 5 × 1 mm3 in dimension containing mouse myoblast cell line36. To validate the muscle tissue development, 
this bioprinted tissue structure was eventually implanted subcutaneously in athymic nude rats. The results showed 
newly formed, oriented myofiber bundles derived from the implanted bioprinted cell-based constructs. In this 
present study, we extended our bioprinting strategy to repair the muscle defect injuries using the bioprinted skel-
etal muscle containing human cell source that is more clinically relevant. Unlike other methods17–20,22, we were 
able to build 3D skeletal muscle constructs (up to 15 × 15 × 15 mm3) that had long parallel multi-layered bundles 
of densely packed, highly viable, and aligned myofibers.
The 3D ITOP system used in this study overcame current limitations on both size and spatial organization 
for the bioengineered skeletal muscle. By simultaneous printing of three components, including the cell-laden 
hydrogel, the sacrificing acellular hydrogel, and the thermoplastic polymeric pillar structure, we were able to 
achieve viable skeletal muscle constructs with structural mimicry and cellular function of native skeletal muscle. 
For the hydrogel-based bioink materials for cell positioning, three major properties are required; (i) relatively 
higher viscosity to maintain homogenous cell suspension before printing, (ii) strong shear-thinning behavior to 
reduce the cell damage during printing, and (iii) rapid gelation to build a 3D tissue structure after printing41. Our 
bioink formulation in this study was optimized based on these requirements36. In our printing design strategy, 
the supporting PCL pillar was essential for the cellular alignment, viability, and differentiation36. We designed the 
Figure 7. Histological examinations. Histological images showed highly aligned newly formed myofibers in 
bioprinted constructs with superior muscle volume maintenance at 4 and 8 weeks post-implantation, while 
severe muscle atrophy and limited muscle regeneration were determined in other groups. Squares in left column 
indicate areas shown in detail with high magnifications. MTS, Masson’s trichrome staining.
www.nature.com/scientificreports/
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cell-laden printing beams to be anchored to the PCL pillar that could place the mechanical tension on the cells 
and drive the cell alignment in a longitudinal direction. The need of the PCL pillar for the cellular alignment and 
maturation was confirmed by low cell viability in a disorganized structure in the non-printed cellular construct 
and the printed constructs without PCL pillar36. This pillar also supported the structural stability without collapse 
or deformation during the culture, resulting in maintaining the multi-layered skeletal muscle organization.
A microchannel structure was created in the bioprinted muscle constructs after removal of the sacrificing 
acellular gelatin hydrogel because the most common drawback of the large-scale cell-based constructs is the lim-
ited supply of oxygen and nutrients into the innermost area31,42. Limited diffusion capacity in the bioengineered 
tissue constructs can result in the induction of a necrotic core, which is unexpected for further functional muscle 
restoration1,10. Gelatin is thermo-sensitive, which is liquid above 37 °C and solid below 25 °C. The gelatin-based 
sacrificing hydrogel was co-printed in parallel with cell-laden patterns at 18 °C. During the printing process, sac-
rificing gelatin hydrogel patterns supported structural stability the cellular patterns before the crosslinking pro-
cess. After crosslinking, gelatin, hyaluronic acid (HA), and glycerol were dissolved out during incubation at 37 °C, 
and the voided space became microchannel in the construct. Our in vitro results also showed low cell viability of 
the large, highly dense constructs (non-printed construct with 30 × 106 cells/ml and 10 × 10 × 3 mm3). Failure of 
non-printed constructs regarding the cell survival and muscle tissue formation emphasizes the need for strategies 
for efficient oxygen and nutrient supply into the implanted cells in the large-scale tissue constructs. Thus, our 
bioprinted muscle constructs had the microchannel structure of 300–400 µm in diameter between the printed 
Figure 8. Immunofluorescent analysis of bioprinted muscle constructs on newly formed muscle. (A) 
Double-immunostaining of MHC/HLA of the retrieved TA muscles (MHC: red, HLA: green). (B) Double-
immunostaining of MHC/HLA of the implanted regions. (C) Quantification of co-localized HLA+/MHC+ cells 
(% of HLA+ cells per MHC+ cells (n = 3, *P < 0.05 compared with non-printed group and **P < 0.05 between 
4 and 8 weeks). Higher skeletal muscle regeneration in bioprinted construct was observed at 4 and 8 weeks 
of implantation. MHC+/HLA+ newly formed myofibers in bioprinted constructs indicate that the implanted 
hMPCs contributed to skeletal muscle regeneration in the defect region (MHC: red, HLA: green, MHC−/HLA+ 
cells: white arrow, MHC+/HLA+ cells: yellow arrow). (D) A cross-sectional view of double-immunostaining 
of MHC/HLA of the bioprinted muscle constructs and (E) Quantification of the diameter of MHC+/HLA+ 
myofibers (µm) (n = 3, 3 random fields per sample, *P < 0.05).
www.nature.com/scientificreports/
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cellular patterns of myofiber bundles. These microchannels maintained the cell viability in the large-scale skel-
etal muscle constructs in high cell densities over 30 × 106 cells/ml during in vitro culture. Moreover, our results 
showed that the cellular constructs with microchannels were viable after implantation because the microchannel 
structure enabled the cells to be alive until the vascular networks were developed in the construct.
To exploit the maximum cellular function, the initial cell density (a range of 10–50 × 106 cells/ml) was con-
siderable on improving the cellular and structural functions of the bioprinted muscle tissue constructs, which 
significantly influenced in the tissue development and dimensional stability. To optimize the initial cell density 
in the bioprinted muscle constructs, the constructs with different cell densities were subcutaneously implanted 
in mice, providing a non-myogenic environment. The histological analyses indicate that the spatial organization 
of the bioprinted muscle constructs was maintained following implantation. Moreover, there was an increas-
ing trend in the volume maintenance (implant’s thickness) and myofiber formation with increasing cell density; 
however, there were no significant differences in the dimensional maintenance and myofiber formation between 
the cell densities of 30 × 106 and 50 × 106 cells/ml. Cell densities higher than 30 × 106 cells/ml may increase oxy-
gen consumption by cells, while diffusion of oxygen decreases in denser tissues. The cell survival and tissue 
formation capability reach a plateau. Therefore, the initial cell density of 30 × 106 cells/ml is optimal for the bio-
printed muscle tissue constructs based on the myofiber formation and thickness maintenance after subcutaneous 
implantation.
Figure 9. Immunofluorescence of vascularization and neural integration of the implanted bioprinted muscle 
constructs. (A) Immunofluorescent images of vWF (green)/α-SMA (red) of the regenerated TA muscles 
at 4 and 8 weeks after implantation. Quantification of (B) vessels/field and (C) area of vessels/field (µm2) 
(n = 3, *P < 0.05 compared with non-treated and gel only groups, **P < 0.05 compared with other groups). 
(D) Immunofluorescent images of NF (green)/AChR (red)/MHC (white) and NF (green)/AChR (red)/HLA 
(white) of the regenerated TA muscles at 4 and 8 weeks after implantation. NF+/AChR+/MHC+ neuromuscular 
junction (middle column, white arrow) was observed in bioprinted muscle constructs. NF+/AChR+/HLA+ 
neuromuscular junction (right column) corresponding area NF+/AChR+/MHC+ (middle column) indicates 
that bioprinted muscle constructs are integrated with host nervous system following implantation. The white 
arrow indicates neuromuscular junction on hMPC-myofibers. (E) Quantification of NMJ/field (×400) (n = 3 
per group, 3 random fields per sample, *P < 0.05 compared with other groups).
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The treatment of the muscle defect is a challenging clinical problem since a relatively large, thick muscle 
defect (>20% of the original muscle mass) suffers functional impartment and has no regenerative capacity3. Thus, 
the bioengineered muscle constructs should be examined using the muscle defect animal model that is more 
clinically relevant. Previously, various bioengineered skeletal muscle constructs were applied to muscle defected 
injury models, such as TA muscle defects in rats29, EDL muscle defects in mice43, quadriceps muscle defects in 
mice44, and vastus lateralis muscle defects in rabbits45; however, these approaches only achieved modest struc-
tural or functional recovery. A standardized rodent model of muscle defect injury created by excising ~20% of 
the middle of the TA muscle was reported37. This model allows functional assessment and shows no recovery of 
muscle weight and tetanic muscle force until 6 months after injury37,46. In this study, we used 30–40% excision of 
TA muscle in addition to ablation of EDL and EHL muscles to prevent compensatory hypertrophy10. Our mod-
ified TA defect model confirmed the irreversible structural and functional deficits with 25% and 54% reduction 
in muscle force and weight, respectively, following 2 months post-injury. For implantation, bioprinted muscle 
constructs were designed to be 10 × 7 × 3.6 mm3 in dimensions after 4–5 days differentiation in culture. The 
outcomes indicate the structural and functional skeletal muscle regeneration using the 3D biomimetic bioprinted 
muscle constructs, while the non-printed construct and cell-free construct (gel only) did not provide any thera-
peutic effects. The regenerated muscle tissue was highly mature and organized with vascular and neural integrity 
at 4 and 8 weeks after implantation. More importantly, the muscle force was recovered by up to 85% of normal 
muscle force at 8 weeks after implantation.
There are several advanced strategies to bioengineer skeletal muscle constructs with cellular orientation. 
For example, a skeletal muscle bundle-like structure with highly organized architecture was fabricated by poly-
dimethylsiloxane (PDMS) molds18. This technique provided the structural maturation and force-generating 
capacity of neonatal rat myogenic cells in the construct. In another study, a scaffold-free skeletal muscle unit was 
fabricated by rolling the monolayer-cultured rat muscle cells into cylindrical forms, and this bioengineered mus-
cle showed a therapeutic potential in vivo29. However, these strategies to bioengineer the skeletal muscles may not 
be clinically feasible. They are not appropriate to build clinically relevant sized muscle constructs that composed 
of multi-layered myofiber bundles. The bioengineered muscle constructs fabricated by the molding method had 
one layer of tri-bundle, and the rolling method showed a thin sheet form of the skeletal muscle unit. Moreover, 
these strategies were tested by the animal cell sources. We previously investigated a possibility of 3D bioprinting 
technology to produce human-scale tissue constructs36. In this study, we utilized 3D bioprinting strategy to build 
3D skeletal muscle constructs using the clinically relevant human primary cells. We believe that this strategy can 
accelerate the clinical translation of the bioengineered skeletal muscles.
Although this study demonstrated the feasibility using 3D bioprinted muscle constructs containing human 
primary muscle cells, several challenges still remained for the future translation. Since we tested the bioprint-
ing strategy for bioengineering skeletal muscle in the immunocompromised animal model, the host responses, 
including inflammatory response and foreign body reaction, in the regeneration process need to be investigated. 
It is also required to examine the systemic effects of the implanted cells for future translation. Thus, a study using 
a preclinical immune-competent animal model with an autologous cell source will be mandatory. In addition, 
accelerating functional integration of bioengineered skeletal muscle by host nerve is the most important factor for 
the clinical success. Adequate innervation of the implanted muscle constructs could prevent the severe muscular 
atrophy to achieve functional muscle recovery47. Therefore, neuronal components that facilitate the muscle cell 
survival, differentiation, and innervation can be incorporated to improve the muscle function. Potential introduc-
tion of neural cells, neurotrophins, or neurotransmitters can be advantageous to develop the accelerated muscle 
function recovery of the bioprinted muscle constructs48–50.
In summary, we designed and fabricated the implantable and biomimetic skeletal muscle construct based 
on the 3D bioprinting strategy for functional muscle regeneration. We examined that the bioprinted muscle 
constructs had the structural and cellular characteristics of the native muscle, which consisted of multi-layered 
myofiber bundles of highly viable, densely packed, and spatially organized hMPCs. We successfully implanted 
these bioprinted muscle constructs in the rat TA muscle defect. Highly organized muscle tissue regeneration with 
the vascularization and host nerve integrity resulted in the restoration of muscle function. Our 3D bioprinted 
skeletal muscles present a possibility for therapeutic effects to treat the muscle defect injuries and have implica-
tions for future translation.
Methods
Human muscle progenitor cell (hMPC) culture. Primary MPCs were taken from biopsies of human 
gracilis muscles (from a 51-year-old and a 64-year-old woman) as previously published51, following the Wake 
Forest University Institutional Review Board (IRB)-approved protocol. Briefly, the muscle biopsies (average 
200 mg) were rinsed in PBS and minced to less than 1 × 1 mm2 following removal of tendon and fat tissues. The 
minced muscles were digested in DMEM (Gibco, Grand Island, NY) containing 0.2% (w/v) of collagenase type I 
(Worthington Biochemical, Lakewood, NJ) and 0.4% (w/v) dispase (Gibco) for 2 h at 37 °C. The digested muscles 
were washed with DMEM/F12 nutrient mix (1:1) (Gibco) consisting of 18% fetal bovine serum (FBS, Valley 
Biomedical Inc., Winchester, VA), 10 ng/ml human epidermal growth factor (hEGF), 1 ng/ml human basic fibro-
blast growth factor (hbFGF), 10 µg/ml human insulin, and 0.4 µg/ml dexamethasone (all from Sigma, St. Louis, 
MO). The muscle fibers were gently pipetted, filtered through a strainer with a pore size of 100 µm, and centri-
fuged at 1500 rpm for 5 min. The resulting pellet was resuspended in the medium. Single muscle fibers were plated 
into 35 mm dishes coated with collagen type I (1 mg/ml, BD, Clontech, Bedford, MA), and incubated overnight 
in the humidified atmospheric air including 5% CO2 at 37 °C. To remove contaminant cells such as fibroblasts, 
the supernatant containing non-adhered hMPCs was collected and transferred into collagen type I-coated 35 mm 
dishes. For primary cell culture, the medium was changed at 4 and 7 days, and the cells showed 80% confluence 
at 8–10 days. The cells were expanded in a growth medium composed of DMEM/high glucose, 20% FBS, 2% 
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chicken embryo extract (Gemini Bio-Products, West Sacramento, CA), and 1% penicillin/streptomycin (Thermo 
Scientific Inc., Waltham, MA). Human MPCs were expanded up to passage 4 for bioprinting.
Bioink preparation. In the printing process, three components were used to print the muscle constructs: the 
cell-laden bioink, the sacrificing acellular bioink, and the supporting PCL pillar. The cell-laden bioink composed 
of 20 mg/ml fibrinogen (Sigma), 35 mg/ml gelatin (Sigma), 3 mg/ml hyaluronic acid (HA, Sigma) and 10% (v/v) 
glycerol (Sigma) was prepared. Briefly, HA was dissolved in DMEM/high glucose at 37 °C with stirring overnight, 
and then glycerol was added to HA solution and stirred for 1 h. Fibrinogen and gelatin were added to the HA/
glycerol solution by gentle shaking at 37 °C for 1 h. After dissolution, the solution was sterilized by a 0.45 µm 
syringe filter (Thermo Scientific). Lastly, the cells were mixed with the bioink by gentle pipetting. The sacrificing 
bioink was prepared by dissolving 35 mg/ml gelatin, 3 mg/ml HA, and 10% (v/v) glycerol in DMEM/high glucose, 
and then filtered. PCL (Mw; 43,000~50,000, Polysciences, Inc., Warrington, PA) was used for the polymeric pillar 
structure.
Bioprinting process. All bioprinted muscle constructs were fabricated using our 3D ITOP system. This 
system is composed of an XYZ stage/controller, multiple dispensing modules, a pneumatic pressure controller, 
and a closed chamber with temperature controller and humidifier. The 3D skeletal muscle constructs with various 
dimensions were designed with 3D computer-aided design (CAD) modeling using our customized software. The 
CAD models were converted to a motion program, path information of each material was generated, and scan-
ning speed, air pressure, and dispensing materials were controlled. The motion program was transferred to the 
operating computer of the 3D ITOP system.
To bioprint skeletal muscle constructs, all materials were aseptically inserted into different cartridges. The 
cell-laden bioink and sacrificial bioink were loaded into sterile plastic syringes at 37 °C and then cooled on ice 
for 10 min. The PCL polymer was loaded into a stainless-steel syringe which was heated at 95 °C for melting. The 
syringes were connected to microscale nozzles (300 µm in diameter, TECDIA, Inc., Tokyo, Japan) and inserted 
into the dispensing module, which was connected to the air pressure controller. The temperature of the closed 
aseptic chamber was maintained at 18 °C during the printing process. Before printing, the nozzles were aligned 
to determine their respective X-Y-Z offsets with minimum 0.01 mm accuracy. The cell-laden bioink was printed 
through a Teflon® nozzle at a speed of 90 mm/min and air pressures ranging from 50 to 70 kPa. The gelatin sacri-
ficial bioink was printed through a Teflon® nozzle at a speed of 160 mm/min at 50–80 kPa. Dispensing speed and 
pressure of the PCL polymer through a metal nozzle was 75 mm/min and 780 kPa, respectively. After printing the 
constructs, 20 UI/ml of thrombin solution (Sigma) were treated on the printed constructs to crosslink the fibrin-
ogen at room temperature for 30 min to 1 h, depending on the size of the constructs. The bioprinted constructs 
were cultured in the growth medium supplemented with aprotinin (20 µg/ml, Sigma). To induce the myofiber 
formation, the bioprinted muscle constructs were cultured in the differentiation medium composed of DMEM/
high glucose, 2% horse serum (Gibco), 1% ITS (Lonza, Basel, Switzerland), 250 nM dexamethasone, 1% penicil-
lin/streptomycin, and 20 µg/ml aprotinin. The medium was changed every other day.
In vitro biological evaluations. Viability and differentiation of hMPCs in the printed and non-printed 
constructs were evaluated in vitro. For comparison, the bioprinted and non-printed (hMPCs in hydrogel with-
out printing) muscle constructs were prepared with the same cell density (30 × 106 cells/ml) and dimension 
(10 × 10 × 3 mm3). For optimizing cell density, the bioprinted muscles with various cell densities (10, 20, 30, and 
50 × 106 cells/ml) were fabricated. The viability of cells within the constructs was examined using a live/dead 
assay/cytotoxicity kit (L-3224; Life Technologies, Carlsbad, CA) and TUNEL assays (Trevigen, Gaithersburg, 
MD) following the manufacturer’s instructions. For the live/dead assay, the bioprinted muscle constructs were 
collected at 1, 6, or 9 days in culture. They were washed with PBS and incubated in the assay solution (50 µl/ml 
Cal-AM and 2 µl/ml Et-D in DMEM/high glucose) at room temperature for 40–60 min. After gently washing the 
constructs with PBS, 4 to 6 images of stained samples were taken using a confocal microscope (Leica TCS LSI 
Macro Confocal; Leica, Microsystems, Wetzlar, Germany). Using these images, the number of live cells (green) 
and dead cells (red) were manually counted, and cell viability (%) was quantified as the ratio of live cells to the 
total cells. To investigate the viability of cells inside of the constructs, a TUNEL assay was performed at 6 days in 
culture. Sections were prepared by fixing the bioprinted muscle constructs with 4% paraformaldehyde for 1 h and 
then cryosectioning with 6 µm thickness. With light microscope images (DM4000, Leica Microsystems) apoptotic 
cells (%) were calculated as the ratio of TUNEL+ cells (brown) to total cells (green) in a blinded fashion (n = 3).
To evaluate the differentiation of hMPCs in the bioprinted constructs and non-printed constructs in vitro, 
immunofluorescent staining for MHC and α-SA/laminin was performed. The constructs were fixed with 4% 
paraformaldehyde for 30 min and permeabilized in methanol at −20 °C for 20 min. For α-SA/laminin staining, 
the constructs were permeabilized in 0.1% Triton X-100 for 20 min and blocked using a serum-free blocking 
agent (X090930-1; Dako, Carpentaria, CA) at room temperature for 1 h. The samples were incubated with mouse 
anti-MF-20 antibody (MF20; 1 µg/ml; Developmental Studies Hybridoma Bank, Iowa City, IA), mouse anti-α-SA 
(a7811; 1:200 dilution; Sigma), and rabbit anti-laminin (ab11575; 1:300 dilution; Abcam, Cambridge, MA) anti-
bodies for 1 h. The samples were then incubated with the secondary antibodies, Texas Red-conjugated anti-mouse 
(TI-2000; 1:200 dilution; Vector Labs, Burlingame, CA) or Alexa 488-conjugated anti-rabbit IgG (A11070; 1:200 
dilution; Invitrogen, Eugene, OR), for 1 h. All antibodies were diluted with antibody diluent (S302283-1; Dako). 
The samples were mounted with VECTASHEILD Mounting Medium (H-1000; Vector Labs) or Prolong® Gold 
Antifade Mountant (P36930; Life Technologies) following incubation in DAPI (D1306; 1:1000 dilution; Life 
Technologies) for 10 min. The stained images were taken using a confocal microscope (FV10i; Olympus, Tokyo, 
Japan). For quantification of myofiber formation in the constructs, the area of MHC+ myofibers (mm2/mm2) 
was measured by using immunofluorescent staining images for MF-20 (×600) in a blinded fashion (n = 3, 4–7 
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random images per each sample). The α-SA+ area (%) and laminin+ area (%) of the non-printed and printed 
constructs were analyzed by immunofluorescent staining images for α-SA/laminin (×1200, n = 3).
In vivo evaluations of bioprinted muscle construct for optimal cell density. All animal procedures 
were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee 
(IACUC) at Wake Forest School of Medicine. Male athymic mice (6–8 weeks old) were obtained from Charles 
River Laboratory (Wilmington, MA). Anesthesia was induced by using 3% isoflurane before surgical procedures, 
and bioprinted muscle constructs were ectopically implanted in the subcutaneous pockets created by dorsal par-
amedian longitudinal incisions, and skin was closed using non-absorbable sutures. For implantation, the bio-
printed muscle constructs with cell densities of 10, 20, 30, and 50 × 106 cells/ml (10 × 10 × 3 mm3 in dimension) 
were cultured in the growth medium for 1 day and then in the differentiation medium for another 3 days. Animals 
were euthanized 1, 2, and 4 weeks after implantation for histologic and immunohistologic analyses (48 nude mice, 
n = 4 in each group).
A rat TA muscle defect model. All animal procedures were performed in accordance with a protocol 
approved by the IACUC at Wake Forest School of Medicine. The muscle defect model was created in RNU rats 
(male, 10–12 weeks old, Charles River Laboratory). Under anesthesia, the rats received a long incision on the skin 
of the left lower leg, and the fascia was separated from the muscles. EDL and EHL muscles were removed to rule 
out compensatory hypertrophy during muscle regeneration, and approximately 30–40% of the middle third of 
TA muscle was excised and weighed. TA muscle weight of each animal was estimated by the following equation: 
y (g) = 0.0017 × body weight (g)–0.071637. The constructs were implanted in the excised sites and covered with 
fascia. Fascia and skin were closed using sutures or surgical staples. In this study, 5 groups were investigated, and 
each group had 4-week and 8-week time points (total 30 rats, n = 3); (1) sham (without defect), (2) non-treated 
(defect only), (3) gel only, (4) non-printed (cells in gel), and (5) bioprinted muscle construct. For implantation, 
the bioprinted muscle constructs were cultured in the growth medium for 1 day and then differentiated for 4–5 
days. Bioprinted muscle constructs (30 × 106 cells/ml) were fabricated with dimensions of 10 × 7 × 3 mm3. For 
non-printed construct, equal volumes of cell-laden composite hydrogel (30 × 106 cells/ml) and gelatin sacrificing 
hydrogel were mixed by gentle pipetting. Groups of gel only, non-printed, and bioprinted constructs had the same 
dimension of the constructs for implantation.
In vivo functional examinations. To evaluate restoration of muscle function, the tetanic force of TA mus-
cle was measured with a dual-mode muscle lever system (Aurora Scientific, Inc., Model 305b, Aurora, Ontario, 
Canada) at 4 and 8 weeks after implantation in a blinded fashion (n = 3)52,53. Rats were anesthetized, and their 
body temperature was maintained at 37 °C. The left foot was attached to a food plate, and the knee and ankle were 
stabilized at 90° angle. Two sterilized platinum needle electrodes were placed in the posterior compartment of 
the lower leg along either side of the peroneal nerve, and the nerve was stimulated using a Grass stimulator (S88) 
at 100 Hz and 10 V with a pulse-width of 0.1 msec. Muscle force (N·mm/Kg) was calculated by (peak isometric 
torque × foot length)/body weight. After the functional assessment, TA muscles of each lower leg were collected 
and weighed. The percentage of TA muscle weight (% of contralateral) was calculated by the ratio of the weight of 
injured TA muscle to that of contralateral TA muscle (n = 3).
Histologic and immunofluorescent analyses. For histologic evaluations of in vivo samples, the har-
vested tissues were freshly frozen in liquid nitrogen and cryosectioned into 6-µm-thick slices. Sectioned tissue 
slides were fixed with 4% paraformaldehyde for 10 min and then stained with H&E and Masson’s trichrome stain. 
The thickness of subcutaneous implants was measured using with H&E-stained longitudinal sections in a blinded 
fashion (n = 4 per each group, 3 random regions per each sample).
For immunofluorescent staining, the paraformaldehyde-fixed tissue sections were permeabilized in metha-
nol at −20 °C and blocked using a serum-free blocking agent for 1 h at room temperature. The blocked sections 
were incubated with primary antibodies at room temperature for 1 h or incubated at 4 °C overnight. The slides 
were treated with secondary antibodies at room temperature for 40 min. Tissue sections were then mounted with 
VECTASHIELD Mounting Medium with DAPI and analyzed by fluorescent imaging using an upright micro-
scope (Leica). Mouse on Mouse (M.O.M.) Kit (BMK-2202; Vector Labs) was used for reducing endogenous 
mouse antibody staining in any mouse-on-mouse application.
To examine the muscle regeneration of implanted bioprinted muscle constructs, tissue sections were 
double-stained with mouse anti-MF20 and rabbit anti-HLA-A (ab52922; 1:100 dilution; Abcam). MHC+ myofib-
ers (/mm2) were counted, and area of MHC+ myofibers (mm2/mm2) was measured with immunofluorescent 
images for MHC (×600) or MHC/HLA (×600) staining in a blinded fashion (n = 4, 3–4 random fields in each 
sample). In addition, we counted the number of HLA+ myofibers (/mm2) and HLA+ myofibers (%) and meas-
ured the area of HLA+ myofibers (mm2/mm2) to evaluate muscle differentiation of implanted hMPCs. Also, 
co-localized HLA+/MHC+ cells (% of HLA+/MHC+ cells per MHC+ cells) were evaluated (n = 3). The diameter 
of MHC+/HLA+ cells (µm) (n = 3, 3 random fields per sample) were measured with immunostaining with MHC/
HLA of cross-sectional samples. All images were analyzed with Image J software (National Institutes of Health, 
Bethesda, MD).
For vascularization, tissue sections were stained with rabbit anti-vWF (A0082; 1:400 dilution; Dako) and 
mouse anti-α-SMA (sc-32251; 1:50 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). Neuromuscular 
junctions were visualized by immunostaining with rabbit anti-NF (N4142; NF200, 1:80 dilution; Sigma)/α-Btx 
(B13423; Alexa Fluor 594 conjugate; 1:100 dilution; Invitrogen), chicken anti-NF (ab4680; 1:1000 dilution; 
Abcam)/rat anti-AChR (ab24719; 1:100 dilution; Abcam)/mouse anti-MF-20 or chicken anti-NF/rat anti-AChR/
rabbit anti-HLA A. Secondary antibodies such as Alexa 488-conjugated anti-rabbit or anti-chicken antibody 
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(A11070; A11039; 1:200 dilution; Invitrogen), Texas Red-conjugated anti-mouse, anti-rabbit, or anti-rat antibody 
(TI-2000; TI-1000; TI-9400; 1:200 dilution; Vector Labs), or Cy5-conjugated anti-mouse or anti-rabbit antibody 
(A10524; A10523; 1:200 dilution; Invitrogen) were used. For quantification of vascularization, vessels/field and 
area of vessels/field (µm2) were measured with immunofluorescent images for vWF/α-SMA (n = 3). NMJ/field 
were counted with immunofluorescent images for MHC/AChR/NF (×400) (n = 3 per group, 3 random fields per 
sample).
Statistical analysis. Results were analyzed with Origin Pro 8.5 (OriginLab Co, Northampton, MA) and 
SPSS software (SPSS, version 19; IBM, Armonk, NY). One-way analysis of variance (ANOVA), Tukey post hoc 
testing and Student t-test were applied to mean comparisons. Variables are expressed as a mean ± standard devia-
tion, and differences between experimental groups were considered statistically significant at P < 0.05.
References
 1. Grasman, J. M., Zayas, M. J., Page, R. L. & Pins, G. D. Biomimetic scaffolds for regeneration of volumetric muscle loss in skeletal 
muscle injuries. Acta biomaterialia 25, 2–15, https://doi.org/10.1016/j.actbio.2015.07.038 (2015).
 2. Charge, S. B. & Rudnicki, M. A. Cellular and molecular regulation of muscle regeneration. Physiological reviews 84, 209–238, https://
doi.org/10.1152/physrev.00019.2003 (2004).
 3. Grogan, B. F. & Hsu, J. R. Volumetric muscle loss. The Journal of the American Academy of Orthopaedic Surgeons 19(Suppl 1), S35–37 
(2011).
 4. Lin, C. H., Lin, Y. T., Yeh, J. T. & Chen, C. T. Free functioning muscle transfer for lower extremity posttraumatic composite structure 
and functional defect. Plastic and reconstructive surgery 119, 2118–2126, https://doi.org/10.1097/01.prs.0000260595.85557.41 
(2007).
 5. Fishman, J. M. et al. Skeletal Muscle Tissue Engineering: Which Cell to Use? Tissue Eng Part B-Re 19, 503–515, https://doi.
org/10.1089/ten.teb.2013.0120 (2013).
 6. Williams, J. K. et al. The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary 
sphincter deficiency. Stem cells translational medicine 4, 286–294, https://doi.org/10.5966/sctm.2014-0114 (2015).
 7. Pecanha, R. et al. Adipose-derived stem-cell treatment of skeletal muscle injury. The Journal of bone and joint surgery. American 
volume 94, 609–617, https://doi.org/10.2106/JBJS.K.00351 (2012).
 8. von Roth, P. et al. Improvement of contraction force in injured skeletal muscle after autologous mesenchymal stroma cell 
transplantation is accompanied by slow to fast fiber type shift. Transfusion medicine and hemotherapy: offizielles Organ der Deutschen 
Gesellschaft fur Transfusionsmedizin und Immunhamatologie 40, 425–430, https://doi.org/10.1159/000354127 (2013).
 9. Qazi, T. H., Mooney, D. J., Pumberger, M., Geissler, S. & Duda, G. N. Biomaterials based strategies for skeletal muscle tissue 
engineering: existing technologies and future trends. Biomaterials 53, 502–521, https://doi.org/10.1016/j.biomaterials.2015.02.110 
(2015).
 10. Kim, J. H., Ko, I. K., Atala, A. & Yoo, J. J. Progressive Muscle Cell Delivery as a Solution for Volumetric Muscle Defect Repair. 
Scientific reports 6, 38754, https://doi.org/10.1038/srep38754 (2016).
 11. Cittadella Vigodarzere, G. & Mantero, S. Skeletal muscle tissue engineering: strategies for volumetric constructs. Frontiers in 
physiology 5, 362, https://doi.org/10.3389/fphys.2014.00362 (2014).
 12. Juhas, M., Ye, J. & Bursac, N. Design, evaluation, and application of engineered skeletal muscle. Methods 99, 81–90, https://doi.
org/10.1016/j.ymeth.2015.10.002 (2016).
 13. Lieber, R. L. & Friden, J. Functional and clinical significance of skeletal muscle architecture. Muscle & nerve 23, 1647–1666 (2000).
 14. Burkholder, T. J., Fingado, B., Baron, S. & Lieber, R. L. Relationship between Muscle-Fiber Types and Sizes and Muscle Architectural 
Properties in the Mouse Hindlimb. J Morphol 221, 177–190, https://doi.org/10.1002/jmor.1052210207 (1994).
 15. Moon du, G., Christ, G., Stitzel, J. D., Atala, A. & Yoo, J. J. Cyclic mechanical preconditioning improves engineered muscle 
contraction. Tissue engineering. Part A 14, 473–482, https://doi.org/10.1089/tea.2007.0104 (2008).
 16. Ostrovidov, S. et al. Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications. Tissue engineering. 
Part B, Reviews 20, 403–436, https://doi.org/10.1089/ten.TEB.2013.0534 (2014).
 17. Bian, W., Liau, B., Badie, N. & Bursac, N. Mesoscopic hydrogel molding to control the 3D geometry of bioartificial muscle tissues. 
Nature protocols 4, 1522–1534, https://doi.org/10.1038/nprot.2009.155 (2009).
 18. Juhas, M., Engelmayr, G. C. Jr., Fontanella, A. N., Palmer, G. M. & Bursac, N. Biomimetic engineered muscle with capacity for 
vascular integration and functional maturation in vivo. Proceedings of the National Academy of Sciences of the United States of 
America 111, 5508–5513, https://doi.org/10.1073/pnas.1402723111 (2014).
 19. Hinds, S., Bian, W., Dennis, R. G. & Bursac, N. The role of extracellular matrix composition in structure and function of 
bioengineered skeletal muscle. Biomaterials 32, 3575–3583, https://doi.org/10.1016/j.biomaterials.2011.01.062 (2011).
 20. Hosseini, V. et al. Engineered contractile skeletal muscle tissue on a microgrooved methacrylated gelatin substrate. Tissue 
engineering. Part A 18, 2453–2465, https://doi.org/10.1089/ten.TEA.2012.0181 (2012).
 21. Ramon-Azcon, J. et al. Gelatin methacrylate as a promising hydrogel for 3D microscale organization and proliferation of 
dielectrophoretically patterned cells. Lab Chip 12, 2959–2969, https://doi.org/10.1039/c2lc40213k (2012).
 22. Aubin, H. et al. Directed 3D cell alignment and elongation in microengineered hydrogels. Biomaterials 31, 6941–6951, https://doi.
org/10.1016/j.biomaterials.2010.05.056 (2010).
 23. Choi, Y. J. et al. 3D Cell Printing of Functional Skeletal Muscle Constructs Using Skeletal Muscle-Derived Bioink. Advanced 
healthcare materials 5, 2636–2645, https://doi.org/10.1002/adhm.201600483 (2016).
 24. Choi, J. S., Lee, S. J., Christ, G. J., Atala, A. & Yoo, J. J. The influence of electrospun aligned poly(epsilon-caprolactone)/collagen 
nanofiber meshes on the formation of self-aligned skeletal muscle myotubes. Biomaterials 29, 2899–2906, https://doi.org/10.1016/j.
biomaterials.2008.03.031 (2008).
 25. Powell, C. A., Smiley, B. L., Mills, J. & Vandenburgh, H. H. Mechanical stimulation improves tissue-engineered human skeletal 
muscle. American journal of physiology. Cell physiology 283, C1557–1565, https://doi.org/10.1152/ajpcell.00595.2001 (2002).
 26. Vader, D., Kabla, A., Weitz, D. & Mahadevan, L. Strain-induced alignment in collagen gels. PloS one 4, e5902, https://doi.
org/10.1371/journal.pone.0005902 (2009).
 27. Flaibani, M. et al. Muscle differentiation and myotubes alignment is influenced by micropatterned surfaces and exogenous electrical 
stimulation. Tissue engineering. Part A 15, 2447–2457, https://doi.org/10.1089/ten.tea.2008.0301 (2009).
 28. Williams, M. L., Kostrominova, T. Y., Arruda, E. M. & Larkin, L. M. Effect of implantation on engineered skeletal muscle constructs. 
Journal of tissue engineering and regenerative medicine 7, 434–442, https://doi.org/10.1002/term.537 (2013).
 29. VanDusen, K. W., Syverud, B. C., Williams, M. L., Lee, J. D. & Larkin, L. M. Engineered skeletal muscle units for repair of volumetric 
muscle loss in the tibialis anterior muscle of a rat. Tissue engineering. Part A 20, 2920–2930, https://doi.org/10.1089/ten.
TEA.2014.0060 (2014).
www.nature.com/scientificreports/
1 4SciEnTiFic RepoRts |  (2018) 8:12307  | DOI:10.1038/s41598-018-29968-5
 30. Corona, B. T., Ward, C. L., Baker, H. B., Walters, T. J. & Christ, G. J. Implantation of in vitro tissue engineered muscle repair 
constructs and bladder acellular matrices partially restore in vivo skeletal muscle function in a rat model of volumetric muscle loss 
injury. Tissue engineering. Part A 20, 705–715, https://doi.org/10.1089/ten.TEA.2012.0761 (2014).
 31. Novosel, E. C., Kleinhans, C. & Kluger, P. J. Vascularization is the key challenge in tissue engineering. Advanced drug delivery reviews 
63, 300–311, https://doi.org/10.1016/j.addr.2011.03.004 (2011).
 32. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257, https://doi.org/10.1038/35025220 
(2000).
 33. Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nature biotechnology 32, 773–785, https://doi.org/10.1038/nbt.2958 
(2014).
 34. Derby, B. Printing and prototyping of tissues and scaffolds. Science 338, 921–926, https://doi.org/10.1126/science.1226340 (2012).
 35. Moroni, L. et al. Biofabrication strategies for 3D in vitro models and regenerative medicine. Nat Rev Mater, https://doi.org/10.1038/
s41578-018-0006-y (2018).
 36. Kang, H. W. et al. A 3D bioprinting system to produce human-scale tissue constructs with structural integrity. Nature biotechnology 
34, 312–319, https://doi.org/10.1038/nbt.3413 (2016).
 37. Wu, X., Corona, B. T., Chen, X. & Walters, T. J. A standardized rat model of volumetric muscle loss injury for the development of 
tissue engineering therapies. BioResearch open access 1, 280–290, https://doi.org/10.1089/biores.2012.0271 (2012).
 38. Zhang, K. et al. 3D bioprinting of urethra with PCL/PLCL blend and dual autologous cells in fibrin hydrogel: An in vitro evaluation 
of biomimetic mechanical property and cell growth environment. Acta biomaterialia 50, 154–164, https://doi.org/10.1016/j.
actbio.2016.12.008 (2017).
 39. Merceron, T. K. et al. A 3D bioprinted complex structure for engineering the muscle-tendon unit. Biofabrication 7, 035003, https://
doi.org/10.1088/1758-5090/7/3/035003 (2015).
 40. Jung, S. Y. et al. 3D printed polyurethane prosthesis for partial tracheal reconstruction: a pilot animal study. Biofabrication 8, 045015, 
https://doi.org/10.1088/1758-5090/8/4/045015 (2016).
 41. Kim, J. H., Yoo, J. J. & Lee, S. J. Three-dimensional cell-based bioprinting for soft tissue regeneration. Tissue Eng Regen Med 13, 1–9 
(2016).
 42. Jain, R. K., Au, P., Tam, J., Duda, D. G. & Fukumura, D. Engineering vascularized tissue. Nature biotechnology 23, 821–823, https://
doi.org/10.1038/nbt0705-821 (2005).
 43. Carosio, S. et al. Generation of eX vivo-vascularized Muscle Engineered Tissue (X-MET). Scientific reports 3, 1420, https://doi.
org/10.1038/srep01420 (2013).
 44. Sicari, B. M. et al. A murine model of volumetric muscle loss and a regenerative medicine approach for tissue replacement. Tissue 
engineering. Part A 18, 1941–1948, https://doi.org/10.1089/ten.TEA.2012.0475 (2012).
 45. Kin, S. et al. Regeneration of skeletal muscle using in situ tissue engineering on an acellular collagen sponge scaffold in a rabbit 
model. ASAIO journal 53, 506–513, https://doi.org/10.1097/MAT.0b013e3180d09d81 (2007).
 46. Corona, B. T. et al. The promotion of a functional fibrosis in skeletal muscle with volumetric muscle loss injury following the 
transplantation of muscle-ECM. Biomaterials 34, 3324–3335, https://doi.org/10.1016/j.biomaterials.2013.01.061 (2013).
 47. Bezakova, G. & Ruegg, M. A. New insights into the roles of agrin. Nat Rev Mol Cell Bio 4, 295–308, https://doi.org/10.1038/Nrm1074 
(2003).
 48. Colombo, E. et al. Autocrine and immune cell-derived BDNF in human skeletal muscle: implications for myogenesis and tissue 
regeneration. The Journal of pathology 231, 190–198, https://doi.org/10.1002/path.4228 (2013).
 49. Chevrel, G., Hohlfeld, R. & Sendtner, M. The role of neurotrophins in muscle under physiological and pathological conditions. 
Muscle & nerve 33, 462–476, https://doi.org/10.1002/mus.20444 (2006).
 50. Ko, I. K. et al. The effect of in vitro formation of acetylcholine receptor (AChR) clusters in engineered muscle fibers on subsequent 
innervation of constructs in vivo. Biomaterials 34, 3246–3255, https://doi.org/10.1016/j.biomaterials.2013.01.029 (2013).
 51. Eberli, D., Soker, S., Atala, A. & Yoo, J. J. Optimization of human skeletal muscle precursor cell culture and myofiber formation in 
vitro. Methods 47, 98–103, https://doi.org/10.1016/j.ymeth.2008.10.016 (2009).
 52. Chiu, C. S. et al. Non-invasive muscle contraction assay to study rodent models of sarcopenia. BMC musculoskeletal disorders 12, 
246, https://doi.org/10.1186/1471-2474-12-246 (2011).
 53. Ashton-Miller, J. A., He, Y., Kadhiresan, V. A., McCubbrey, D. A. & Faulkner, J. A. An apparatus to measure in vivo biomechanical 
behavior of dorsi- and plantarflexors of mouse ankle. J Appl Physiol (1985) 72, 1205–1211 (1992).
Acknowledgements
We thank H. S. Kim, J. S. Lee, and T. Bledsoe for a surgical procedure, Regenerative Medicine Clinical Center 
(RMCC) for hMPCs isolation, M. Devarasetty for imaging, and Y. M. Ju for technical assistance. The authors 
thank K. Klein at the Wake Forest Clinical and Translational Science Institute (UL1 TR001420) for editorial 
assistance. This work was supported by the Army, Navy, NIH, Air Force, VA and Health Affairs to support 
the AFIRM II effort under Award No. W81XWH-14-2-0004. The U.S. Army Medical Research Acquisition 
Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. 
Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily 
endorsed by the Department of Defense. J.H.K. was supported by Basic Science Research Program through the 
National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology 
(2012R1A6A3A03040684).
Author Contributions
J.H.K., J.J.Y., and S.J.L. designed the study. J.H.K., Y.-J.S., and H.-W.K. performed in vitro experiments. J.H.K., 
I.K.K., and Y.K.L. performed in vivo experiments. J.H.K. and S.J.L. wrote the manuscript. J.J.Y., A.A., and S.J.L. 
provided direction and supervised the work. All authors contributed to editing the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-29968-5.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 5SciEnTiFic RepoRts |  (2018) 8:12307  | DOI:10.1038/s41598-018-29968-5
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
